Dyax Corp

Dyax Corp
Share

Dyax Corp

 •  November 16, 2016

CUVITRU, now available in the U.S., expands Shire’s immunoglobulin portfolio of treatment options to meet the unique needs of children and adults living with primary immunodeficiency
Shire plc (LSE: SHP, NASDAQ: SHPG) announces the launch of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] , the first and only Subcutaneous 20% treatment...

Dyax Corp

 •  October 18, 2016

ONIVYDE, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), is the first and only treatment approved for this patient population based on pivotal Phase 3 data (NAPOLI-1) showing increased overall survival i,ii [Dublin, Ireland] – October 18, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the European Commission (EC) has...

Dyax Corp

 •  September 14, 2016

Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites
Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the United States Food and Drug Administration (FDA) has granted approval for CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in adult and pediatric...

Dyax Corp

 •  December 6, 2015

Preclinical Data Support Thesis That Factor XIIa Inhibition Has the Potential to be an Effective Antithrombotic, Without Bleeding Side Effects
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) today announced a poster presentation describing preclinical data for DX-4012, the Company's fully human monoclonal antibody to activated Factor...

Dyax Corp

 •  November 9, 2015

Results Provide Important Clinical Proof-of-Concept, Dose Response and Safety Information in the Target Patient Population
BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) today announced that two oral presentations describing clinical data from its DX-2930 Phase 1b study were presented at the American College of Allergy, Asthma, and...

Dyax Corp

 •  November 2, 2015

DUBLIN and BURLINGTON, Massachusetts, November 2, 2015 /PRNewswire/ --DX-2930 has potential to expand HAE-treated patients and achieve annual worldwide sales of up to $2 billion with exclusivity beyond 2030 DX-2930 is supported by proof-of-concept Phase 1B data, demonstrating a > 90% reduction in HAE attacks compared to placebo in the 300mg/400mg...

Dyax Corp

 •  November 2, 2015

BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) announced today the cancellation of its previously scheduled Research and Development (R&D) Day, which was set to take place onMonday, November 2, 2015, in New York City.
In a news release issued separately today, Dyax announced that it has entered into a definitive merger agreement with...

Dyax Corp

 •  October 28, 2015

BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2015. Dyax will host a webcast to review these results in conjunction with the Company's Research and Development Day on Monday, November 2, 2015 at 8:00 a.m. (ET).Recent highlights include:Protocol finalized...

Dyax Corp

 •  October 27, 2015

Dyax Corp. (NASDAQ: DYAX) will release third quarter financial results onWednesday, October 28, 2015 after market close. In lieu of the previously announced third quarter 2015 financial results conference call and webcast, the Dyax management team will review the Company's third quarter 2015 financial results in conjunction with the Research and...

Dyax Corp

 •  September 30, 2015

BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ:DYAX) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending DX-2930 for designation as an orphan medicinal product for the treatment of hereditary angioedema (HAE). Dyax is developing DX-2930, an ...